EDITOR'S BLOG

From China to the Culture Dish: A Brief History of the CHO cell line

By Gareth Macdonald contact

- Last updated on GMT

Related tags: Chinese hamster ovary cell

Scientists say the Chinese hamster genome published last month will help biomanufacturers develop better CHO cell lines. 

This BioPharma-Reporter.com timeline traces the hamster's journey from the deserts of China to the research labs of Harvard in the mid-50s and on to the manufacturing facilities of today's $125bn biomanufacturing industry. 

CHO recap

Since they were first isolated in the late 1950s, Chinese hamster ovary (CHO) cells have become the expression system of choice for biomanufacturers with the firms behind top sellers like Rituxan, Humira and Enbrel all using them to manufacture their products.

But while scientists have improved CHO lines for biomanufacturing - increasing yields and improving selectability - the lack of a reference sequence for the Chinese hamster (Cricetulus griseus) has meant such work relied on random mutagenesis rather than genetic engineering.

This has now changed according to the authors of the draft Chinese hamster genome published in Nature, who say the 2.4-Gbase, 24,044-gene sequence will aid bioprocessing systems analysis and in cell line engineering.

Author Prof Bernhard Palsson, of the University of California, San Diego, told BioPharma-Reporter.com that: "This sequence will be the reference sequence for all genome-scale analysis of CHO cell lines​," adding that "the current paper also has sequences for 7 CHO cell lines of various origins​."

This information – and indeed the availability of a reference comparator – is likely to be of considerable use to biomanufacturers according to Prof Palsson, particularly those striving to improve production yields.

"The biopharmaceutical industry is worth about $125bn per year in sales at high profit margins. The majority of therapeutic protein are made in CHO cells. The current paper, along with the 2011 publication of the CHO K1 sequence puts this industry firmly into the genome era

"The genome-scale era for CHO is likely to substantially improve CHO cell lines as production hosts and have a far reaching impact on this industry, just as whole genome sequences did for e. coli and yeast as production hosts​."

BioPharma-Reporter.com would like to thank Prof. Wei-Shou Hu from the University of Minnesota who was kind enough to send a copy of his paper "Recombinant Protein Therapeutics from CHO Cells - 20 years and Counting​."

Related news

Show more

Related products

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

Scalability, Quality, and Speed with Transposons

Scalability, Quality, and Speed with Transposons

Wheeler Bio | 20-Oct-2022 | Technical / White Paper

To solve for the significant bottlenecks often presented by conventional cell line development processes, this article discusses how Wheeler Bio is leveraging...

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

Discover the world of upstream bioprocessing

Discover the world of upstream bioprocessing

Eppendorf Bioprocess Solutions | 07-Sep-2022 | Technical / White Paper

A must-read for all bioprocess scientists: This bundle of four ebooks created by Eppendorf guides you through the world of upstream bioprocessing.

Related suppliers

Follow us

Products

View more

Webinars